抗C3与抗C4自身抗体在狼疮性肾炎中的临床相关性
该研究在85例狼疮性肾炎(LN)患者中检测抗C3和抗C4 IgG自身抗体,并纵向随访8年(295份样本)。抗C3 IgG与低补体血症、抗dsDNA、IV型LN及BILAG肾脏评分活动相关,且初始抗C3阳性可预测当前及未来疾病加重,与抗dsDNA联合预测更优。
要点
- 抗C3 IgG与LN疾病活动性临床指标相关性优于抗C4。
- 初始抗C3阳性可预测当前及未来LN病情加重。
- 抗C3联合抗dsDNA预测LN复发优于单一指标。
核心结论
- 抗C3与抗C4自身抗体在LN中常无交叉反应,抗C3作为疾病活动生物标志物更具临床关联和预测价值。
研究设计与样本
- LN队列研究纳入85例患者,纵向随访8年,共295份样本,进行横断面和纵向分析。
主要发现
- 抗C3 IgG与低补体血症、抗dsDNA、IV型LN及BILAG肾脏评分活动相关。
- 纵向分析中,初始抗C3阳性预测当前及未来疾病加重(BILAG肾脏评分转为A类)。
- 抗C3联合抗dsDNA预测疾病加重的效果优于两者单独使用。
关键数值与推荐
- 抗C3反应性与抗C4无关,两者常不交叉反应。
- 抗C3阳性与BILAG肾脏评分活动相关,联合抗dsDNA可预测BILAG肾脏评分转为A类。
临床怎么用
- 建议将抗C3/C3b定量纳入LN常规临床实践,以改善疾病管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Complement system overactivation is pivotal in lupus nephritis (LN) pathophysiology. Considering that anti-C3 autoantibodies play a significant role in LN pathophysiology, we explored them as disease activity biomarkers and compared them to the ones against the homologous protein, C4. METHODS: We investigated the presence of anti-C3 and anti-C4 IgG autoantibodies in a LN cohort (N = 85 patients) and monitored their changes over time. We correlated autoantibody presence with clinical parameters. We conducted cross-sectional and longitudinal analyses (N = 295 samples, 8 years follow-up) to explore associations between autoantibodies and disease progression. Antigen-specific anti-C3 or anti-C4 IgG were purified from plasma by affinity chromatography and their reactivity was tested for cross-reactivity against purified C3 or C4 by enzyme-linked immunosorbent assay (ELISA). RESULTS: The reactivity against C3 was independent of C4. Our study revealed distinct roles for anti-C3 and anti-C4 in LN. Anti-C3 IgG exhibited stronger clinical correlations than anti-C4, showing associations with hypocomplementemia, anti-dsDNA, class IV LN, and active disease according to British Isles Lupus Assessment Group (BILAG) renal score. In a longitudinal analysis, anti-C3 positivity at initial sampling predicted present and future disease exacerbation alone and even better when combined with anti-dsDNA, as indicated by a transition to BILAG category A. CONCLUSION: Our research provides insights into anti-C3/C3b and anti-C4 autoantibodies in LN, revealing that they are often not cross-reactive. Anti-C3 utility as disease activity biomarkers is underscored by its stronger clinical associations and predictive value for future flares. Combining anti-C3 and anti-dsDNA out-performs the 2 factors alone, suggesting that the incorporation of anti-C3/C3b quantification into routine clinical practice could improve LN management.
引用
- Vasilev V, Artero MR, Petkova M, et al. Clinical Relevance of Anti-C3 and Anti-C4 Autoantibodies in Lupus Nephritis. Kidney Int Rep. 2024. PMID: 38707805. doi:10.1016/j.ekir.2024.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。